Literature DB >> 7811014

Sterol composition of Cryptococcus neoformans in the presence and absence of fluconazole.

M A Ghannoum1, B J Spellberg, A S Ibrahim, J A Ritchie, B Currie, E D Spitzer, J E Edwards, A Casadevall.   

Abstract

Analysis of the sterol compositions of 13 clinical isolates of the pathogenic yeast Cryptococcus neoformans obtained from five patients with recurring cryptococcal meningitis showed that, unlike Candida albicans, the major sterols synthesized by this yeast were obtusifoliol (range, 21.1 to 68.2%) and ergosterol (range, 0.0 to 46.5%). There was considerable variation in the sterol contents among the 13 isolates, with total sterol contents ranging from 0.31 to 5.9% of dry weight. The isolates from the five patients who had relapses had different total sterol contents and compositions in comparison with those of the pretreatment isolates, indicating either that the sterols had been changed by therapy or that the patients were infected with new isolates with different sterol compositions. Growth of the cryptococcal isolates in the presence of subinhibitory concentrations of fluconazole (0.25x the MIC) significantly altered the sterol content and pattern. The total sterol content decreased in nine isolates and increased in four isolates in response to pretreatment with fluconazole. Fluconazole had no consistent effect on ergosterol levels. In contrast, fluconazole caused a decrease in obtusifoliol levels and an increase in 4,14-dimethylzymosterol levels in all isolates. These results indicate extensive diversity in sterol content, sterol composition, and sterol synthesis in response to subinhibitory concentrations of fluconazole in C. neoformans strains. We propose that fluconazole inhibits the sterol synthesis of C. neoformans by interfering with both 14 alpha-demethylase-dependent and -independent pathways. No correlation between the sterol compositions of C. neoformans isolates and their susceptibilities to fluconazole was found.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7811014      PMCID: PMC284679          DOI: 10.1128/AAC.38.9.2029

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.

Authors:  M S Saag; W G Powderly; G A Cloud; P Robinson; M H Grieco; P K Sharkey; S E Thompson; A M Sugar; C U Tuazon; J F Fisher
Journal:  N Engl J Med       Date:  1992-01-09       Impact factor: 91.245

2.  Restriction fragment polymorphism in mitochondrial DNA of Cryptococcus neoformans.

Authors:  A Varma; K J Kwon-Chung
Journal:  J Gen Microbiol       Date:  1989-12

3.  Reference high-efficiency nonpolar packed columns for the gas-liquid chromatography of nanogram amounts of steroids. I. Retention time data.

Authors:  F A Vandenheuvel; A S Court
Journal:  J Chromatogr       Date:  1968-12-17

Review 4.  Sterols in Candida albicans mutants resistant to polyene or azole antifungals, and of a double mutant C. albicans 6.4.

Authors:  C A Hitchcock; N J Russell; K J Barrett-Bee
Journal:  Crit Rev Microbiol       Date:  1987       Impact factor: 7.624

5.  Saperconazole: a selective inhibitor of the cytochrome P-450-dependent ergosterol synthesis in Candida albicans, Aspergillus fumigatus and Trichophyton mentagrophytes.

Authors:  H Vanden Bossche; P Marichal; G Willemsens; D Bellens; J Gorrens; I Roels; M C Coene; L Le Jeune; P A Janssen
Journal:  Mycoses       Date:  1990 Jul-Aug       Impact factor: 4.377

6.  Effects of itraconazole on cytochrome P-450-dependent sterol 14 alpha-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans.

Authors:  H Vanden Bossche; P Marichal; L Le Jeune; M C Coene; J Gorrens; W Cools
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

7.  Extensive allelic variation in Cryptococcus neoformans.

Authors:  A Casadevall; L F Freundlich; L Marsh; M D Scharff
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

Review 8.  Azole antifungal agents: emphasis on new triazoles.

Authors:  M S Saag; W E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

Review 9.  Azole antifungal agents.

Authors:  G P Bodey
Journal:  Clin Infect Dis       Date:  1992-03       Impact factor: 9.079

Review 10.  Cryptococcosis.

Authors:  J R Perfect
Journal:  Infect Dis Clin North Am       Date:  1989-03       Impact factor: 5.982

View more
  27 in total

Review 1.  Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.

Authors:  M A Ghannoum; L B Rice
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

Review 2.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

3.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

4.  Effects of amphotericin B and three azole derivatives on the lipids of yeast cells of Paracoccidioides brasiliensis.

Authors:  R C Hahn; J S Hamdan
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

5.  A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei.

Authors:  H Sanati; P Belanger; R Fratti; M Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

Review 6.  Use of amphotericin B with azole antifungal drugs: what are we doing?

Authors:  A M Sugar
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

7.  Analysis of sphingolipids, sterols, and phospholipids in human pathogenic Cryptococcus strains.

Authors:  Ashutosh Singh; Andrew MacKenzie; Geoffrey Girnun; Maurizio Del Poeta
Journal:  J Lipid Res       Date:  2017-08-15       Impact factor: 5.922

8.  In vitro and in vivo effects of 14alpha-demethylase (ERG11) depletion in Candida glabrata.

Authors:  H Nakayama; N Nakayama; M Arisawa; Y Aoki
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.

Authors:  J Mukherjee; M D Scharff; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

10.  Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model.

Authors:  R E Lewis; B C Lund; M E Klepser; E J Ernst; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.